Adverse Events and Drug Resistance in Critically Ill Patients Treated with Colistimethate Sodium: A Review of the Literature

References

• Vargas L. Estudio prospectivo del uso de colistina en el Servicio de Cuidados Intensivos del Hospital Nacional Edgardo Rebagliati Martins. Univ Nacional de San marcos. 2018;2(1):235–270.
   Google Scholar
• Storm DR, Rosenthal KS, Swanson PE. Polymyxin and Related Peptide Antibiotics. Annu Rev Biochem. 1977;46(1):723–763. doi:10.1146/annurev.bi.46.070177.003451
   PubMedGoogle Scholar
• Coscia L, Causa P, Giuliani E, Nunziata A. Pharmacological properties of new neuroleptic compounds. Arzneimittelforschung. 1975;25(9):1436–1442.
   Web of Science ®Google Scholar
• Medina J. Actualización acerca de colistina (polimixina E): aspectos clínicos, PK/PD y equivalencias. Revista Médica del Uruguay. 2017. doi:10.29193/RMU.33.3.5
   Google Scholar
• Hancock R. The bacterial outer membrane as a drug barrier. Trends Microbiol. 1997;5(1):37–42. doi:10.1016/S0966-842X(97)81773-8
   PubMed Web of Science ®Google Scholar
• Alavi M, Antonic V, Stojadinovic A, Zhang B, Mina Izadjoo M. Pseudomonas aeruginosa induces pigment production and enhances virulence in a white phenotypic variant of Staphylococcus aureus. Infection and Drug Resistance. 2013;175. doi:10.2147/IDR.S49039
   PubMedGoogle Scholar
• Mlynarcik P, Kolar M. Molecular mechanisms of polymyxin resistance and detection of mcr genes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163(1):28–38. doi:10.5507/bp.2018.070
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–3436. doi:10.1128/AAC.01361-08
   PubMed Web of Science ®Google Scholar
• Koch-Weser J. Adverse Effects of Sodium Colistimethate: manifestations and Specific Reaction Rates During 317 Courses of Therapy. Ann Intern Med. 1970;72(6):857. doi:10.7326/0003-4819-72-6-857
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. doi:10.1186/cc3995
   PubMed Web of Science ®Google Scholar
• El-Sayed Ahmed MAEG, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). Em Microbes Infections. 2020;9(1):868–885. doi:10.1080/22221751.2020.1754133
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596. doi:10.1097/01.CCM.0000217961.75225.E9
   PubMed Web of Science ®Google Scholar
• Agarossi A, Pintaudi G. Antimicrobials and Progression to Septic Shock in Severe Sepsis Patients: is Delay the Only Thing That Matters? Crit Care Med. 2017;45(9):e988–e989. doi:10.1097/CCM.0000000000002521
   PubMedGoogle Scholar
• Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12):1277–1282. doi:10.1016/j.jclinepi.2011.01.011
   PubMed Web of Science ®Google Scholar
• Rosas Espinoza C, Caro Teller JM. Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados [Incidence of intravenous colistin nephrotoxicity in hospitalized patients]. Rev Esp Quimioter. 2021;34(1):12–17. doi:10.37201/req/082.2020
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Bidell MR, Gandhi RG, et al. Colistin Nephrotoxicity: meta-Analysis of Randomized Controlled Trials. Open Forum Infectious Dis. 2021;8(2):ofab026. doi:10.1093/ofid/ofab026
   PubMed Web of Science ®Google Scholar
• Martínez J, Loiácono F, Alemano G, Ríos F, Aguilar L, Cestari J. Insuficiencia renal aguda asociada al tratamiento con colistín en Unidad de Cuidados Intensivos. Rev Nefrol Dial Traspl. 2014;34(3):108–111.
   Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–1726. doi:10.1093/cid/cis286
   PubMed Web of Science ®Google Scholar
• Meraz-Muñoz A, Gomez-Ruiz I, Correa-Rotter R, Ramirez-Sandoval JC. Chronic kidney disease after acute kidney injury associated with intravenous colistin use in survivors of severe infections: a comparative cohort study. J Crit Care. 2018;44:244–248. doi:10.1016/j.jcrc.2017.11.022
   PubMed Web of Science ®Google Scholar
• Mercado MG, Smith DK, Guard EL. Acute Kidney Injury: diagnosis and Management. Am Fam Physician. 2019;100(11):687–694.
   PubMed Web of Science ®Google Scholar
• Levey AS, James MT. Acute Kidney Injury. Ann Intern Med. 2017;167(9):ITC66–ITC80. doi:10.7326/AITC201711070
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57(12):6319–6324. doi:10.1128/AAC.00254-13
   PubMed Web of Science ®Google Scholar
• Hori Y, Aoki N, Kuwahara S, et al. Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity. J Am Soc Nephrol. 2017;28(6):1783–1791. doi:10.1681/ASN.2016060606
   PubMed Web of Science ®Google Scholar
• Hori Y. Correction: megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity. J Am Soc Nephrol. 2022;33(4):872. doi:10.1681/ASN.2022010083
   PubMed Web of Science ®Google Scholar
• Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21(1):91–94. doi:10.1038/5030
   PubMed Web of Science ®Google Scholar
• Events adverse related to colistin, de BioRender.com; 2022. https://app.biorender.com/biorender-templates. Accessed February 21, 2023.
   Google Scholar
• Tabish M, Mahendran M, Ray A, Vikram NK. Colistin-induced acquired Bartter-like syndrome: an unusual cause of the meltdown. BMJ Case Rep. 2020;13(2):e232630. doi:10.1136/bcr-2019-232630
   PubMedGoogle Scholar
• Jiménez-Mejías ME, Pichardo-Guerrero C, Márquez-Rivas FJ, Martín-Lozano D, Prados T, Pachón J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002;21(3):212–214. doi:10.1007/s10096-001-0680-2
   PubMed Web of Science ®Google Scholar
• Jeong ES, Kim G, Moon KS, et al. Characterization of urinary metabolites as biomarkers of colistin-induced nephrotoxicity in rats by a liquid chromatography/mass spectrometry-based metabolomics approach. Toxicol Lett. 2016;248:52–60. doi:10.1016/j.toxlet.2016.02.018
   PubMed Web of Science ®Google Scholar
• Fotakopoulos G, Makris D, Chatzi M, Tsimitrea E, Zakynthinos E, Fountas K. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir. 2016;158(3):603–610. doi:10.1007/s00701-016-2702-y
   PubMed Web of Science ®Google Scholar
• De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol. 2016;23(1):68–75. doi:10.1111/ene.12789
   PubMed Web of Science ®Google Scholar
• Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection, and treatment implications. Expert Rev Anti Infect Ther. 2018;16(4):289–306. doi:10.1080/14787210.2018.1453807
   PubMed Web of Science ®Google Scholar
• Feng Y. Transferability of MCR-1/2 Polymyxin Resistance: complex Dissemination and Genetic Mechanism. ACS Infect Dis. 2018;4(3):291–300. doi:10.1021/acsinfecdis.7b00201
   PubMed Web of Science ®Google Scholar
• Srinivas P, Rivard K. Polymyxin Resistance in Gram-negative Pathogens. Curr Infect Dis Rep. 2017;19(11):38. doi:10.1007/s11908-017-0596-3
   PubMed Web of Science ®Google Scholar
• Son SJ, Huang R, Squire CJ, Leung IKH. MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance. Drug Discov Today. 2019;24(1):206–216. doi:10.1016/j.drudis.2018.07.004
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, et al. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae. Sci Rep. 2021;11:18. doi:10.1038/s41598-020-78098-4
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant Acinetobacter baumannii: a Propensity Score-Matched Analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients. Pharmaceutics. 2022;14(1):31. doi:10.3390/pharmaceutics14010031
   Web of Science ®Google Scholar
• Arias IM, Pobes A, Baños M, Cistatina C. Nuevo marcador de función renal [Cystatin C. New marker of renal function]. Nefrologia. 2005;25(3):217–220.
   PubMed Web of Science ®Google Scholar
• Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine, and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024–2031. doi:10.1093/ndt/gfg349
   PubMed Web of Science ®Google Scholar
• Oyabu C, Hayashi N, Sugiyama D, et al. Rinsho Byori. Rinsho Byori. The Japanese Journal of Clinical Pathology. 2006;54(12):1204–1208.
   PubMedGoogle Scholar
• Tamba K, Kusano E, Ando Y, Asano Y. Nihon Jinzo Gakkai Shi. Nihon Jinzo Gakkai Shi. 2001;43(8):646–650.
   PubMedGoogle Scholar
• Hotta O, Yusa N, Mukaiyama I, Taguma Y. Nihon Jinzo Gakkai Shi. Nihon Jinzo Gakkai Shi. 1999;41(8):797–803.
   PubMedGoogle Scholar
• Quiroga C, Nastro M, Di Conza J. Current scenario of plasmid-mediated colistin resistance in Latin America. Revista Argentina de Microbiología. 2019;51(1):93–100. doi:10.1016/j.ram.2018.05.001
   PubMed Web of Science ®Google Scholar
• Xu Y, Wei W, Lei S, Lin J, Srinivas S, Feng Y. An Evolutionarily Conserved Mechanism for Intrinsic and Transferable Polymyxin Resistance. mBio. 2018;9(2):e02317. doi:10.1128/mBio.02317-17
   PubMed Web of Science ®Google Scholar
• Arrayasillapatorn N, Promsen P, Kritmetapak K, Anunnatsiri S, Chotmongkol W. Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: significance of Drug Doses Adjusted to Ideal Body Weight. Int J Nephrol. 2021;2021:7795096. doi:10.1155/2021/7795096
   PubMed Web of Science ®Google Scholar
• Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomized trial. Ann Intensive Care. 2016;6(1):26. doi:10.1186/s13613-016-0127-7
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–1728. doi:10.1086/599225
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):349–352. doi:10.1016/j.ijantimicag.2013.12.002
   PubMed Web of Science ®Google Scholar
• Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13(1):380. doi:10.1186/1471-2334-13-380
   PubMed Web of Science ®Google Scholar
• Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013;17(4):R174. doi:10.1186/cc12853
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: is This the Right Dosing Strategy? A Preliminary Study. Clin Infectious Dis. 2012;54(12):1720–1726. doi:10.1093/cid/cis286
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884. doi:10.1093/cid/cir611
   PubMed Web of Science ®Google Scholar
• Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503–4505. doi:10.1128/AAC.01707-09
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Levcovich A, et al. Eficacia y seguridad de la colistina: estudio prospectivo comparativo de cohortes. J Quimioterapia antimicrobiana. 2010;65(5):1019–1027. doi:10.1093/jac/dkq069
   PubMed Web of Science ®Google Scholar
• Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of Last Resort: polymyxin Resistance. Infect Dis Clin North Am. 2016;30(2):391–414. doi:10.1016/j.idc.2016.02.005
   PubMed Web of Science ®Google Scholar
• Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev. 2017;30(2):557–596. doi:10.1128/CMR.00064-16
   PubMed Web of Science ®Google Scholar
• Cheng YH, Lin TL, Lin YT, Wang JT. Amino Acid Substitutions of CrrB Responsible for Resistance to Colistin through CrrC in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60(6):3709–3716. doi:10.1128/AAC.00009-16
   PubMed Web of Science ®Google Scholar
• Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: to Combine or Not to Combine? Antibiotics. 2019;8(2):38. doi:10.3390/antibiotics8020038
   Web of Science ®Google Scholar
• Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49(5):526–535. doi:10.1016/j.ijantimicag.2016.11.029
   PubMed Web of Science ®Google Scholar
• Lima WG, Alves MC, Cruz WS, Paiva MC. Chromosomally encoded and plasmid-mediated polymyxins resistance in Acinetobacter baumannii: a huge public health threat. Eur J Clin Microbiol Infect Dis. 2018;37(6):1009–1019. doi:10.1007/s10096-018-3223-9
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Gupta J, et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 2013;23(7):1155–1162. doi:10.1101/gr.154328.112
   PubMed Web of Science ®Google Scholar
• Trebosc V, Gartenmann S, Tötzl M, et al. Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates. mBio. 2019;10(4):e01083–19. doi:10.1128/mBio.01083-19
   PubMed Web of Science ®Google Scholar
• Nhu N, Riordan DW, Do HoanNhu T, et al. The induction and identification of novel Colistin resistance mutations in Acinetobacter baumannii and their implications. Sci Rep. 2016;6:28291. doi:10.1038/srep28291.
   PubMed Web of Science ®Google Scholar
• Muller C, Plésiat P, Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011;55(3):1211–1221. doi:10.1128/AAC.01252-10
   PubMed Web of Science ®Google Scholar
• Miller AK, Brannon MK, Stevens L, et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011;55(12):5761–5769. doi:10.1128/AAC.05391-11
   PubMed Web of Science ®Google Scholar
• Vandeplassche E, Sass A, Lemarcq A, Dandekar AA, Coenye T, Crabbé A. In vitro evolution of Pseudomonas aeruginosa AA2 biofilms in the presence of cystic fibrosis lung microbiome members. Sci Rep. 2019;9(1):12859. doi:10.1038/s41598-019-49371-y
   PubMedGoogle Scholar
• Salgado G, Landa M, Masevicius D, et al. Insuficiencia renal aguda según RIFLE y AKIN: estudio multicéntrico. Medicina Intensiva. 2014;38(5):271–277. doi:10.1016/j.medin.2013.04.007
   PubMedGoogle Scholar